Actively Recruiting
Effect of Empagliflozin on Inflammation
Led by Hotel Dieu de France Hospital · Updated on 2025-12-18
100
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood. He hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect. To document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent will develop inflammation following stenting. This is documenting by a higher level of C-Reactive Protein 24 hours after the procedure. Patients who will participate in the study, will receive empagliflozin or a placebo tablet for 3 days prior to the revascularisation procedure. CRP and other inflammatory markers will be measured before intervention and 24 hours later. The goal is to demonstrate a lower rise in CRP following intervention in patients treated with empagliflozin vs. those who have received a placebo.
CONDITIONS
Official Title
Effect of Empagliflozin on Inflammation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery
- Age 18 years or older
You will not qualify if you...
- Patients who have been taking an SGLT-2 inhibitor during the last month
- Patients who are receiving any anti-inflammatory medication such as immunosuppressors, steroids, or NSAIDs
- Patients with underlying inflammatory conditions such as rheumatoid arthritis, infection, or active malignancy
- Patients with an acute coronary syndrome within the last month
- Intervention on a restenotic lesion or lesion in a saphenous vein graft
- Creatinine clearance less than 30 mL/min
- Patients treated with devices other than balloons and stents (e.g., lithotripsy, rotational atherectomy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hotel Dieu de France
Beirut, Beirut, Lebanon, 00000
Actively Recruiting
Research Team
R
Rabih R Azar, MD, MPH
CONTACT
G
Georges G Hage, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here